Product
ChAdOx1-S
Aliases
ChAdOx1-S not less than 2.5 × 10^8 infectious units
4 clinical trials
1 indication
Indication
COVID-19Clinical trial
A 2-Stage, Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2023-10-02
Clinical trial
A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 VaccineStatus: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
Immunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is "Mix and Match" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic?Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
Assessment of the Immunogenicity and Safety of Marketed Vaccines for COVID-19 After Regular Schedule and Adapted Vaccine Schedules and Routes: BNT162b2, mRNA-1273 Vaccine and ChAdOx1-S [Recombinant]Status: Completed, Estimated PCD: 2021-11-03